Intellectual Property: Enough, Already!

According to an admittedly imperfect source, tamoxifen was originally viewed as a possible contraceptive. Today thousands of women are alive because tamoxifen is an incredibly valuable chemotherapy drug used to treat breast cancer. Imagine if ICI (the company that first investigated tamoxifen) had granted the kind of license proposed above. Clearly breast cancer drugs do not compete with contraceptives. ICI would, in effect, have given away incredibly valuable IP under the idiotic proposal outlined above. Continue Reading →